Showing 2091-2100 of 4063 results for "".
- JPM: BioNTech Hikes COVID-19 Vaccine Output to 2B Doses in 2021—And Plans a Bigger Label, Toohttps://modernod.com/news/jpm-biontech-hikes-covid-19-vaccine-output-to-2b-doses-in-2021-and-plans-a-bigger-label-too/2478746/With its Pfizer-partnered COVID-19 vaccine authorized in the U.S., Europe, the U.K. and a slate of other countries, German mRNA specialist BioNTech is wasting no time scaling up its 2021 pandemic ambitions—namely, 2 billion shots by year-end, plus a slate of new approvals and a temperature-stable
- Regenxbio Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meetinghttps://modernod.com/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting/2478516/Regenxbio announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format. The first presentation will feature data from the RGX-314 phase 1/2 subret
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- Oxurion to Present New Preclinical Data on THR-687 at EURETINA 2020 Virtual Meetinghttps://modernod.com/news/oxurion-to-present-new-preclinical-data-on-thr-687-at-euretina-2020-virtual-meeting/2478342/Oxurion NV announced that it will present new preclinical data on THR-687 at the European Society of Retina Specialists (EURETINA) 2020 Virtual Meeting taking place October 2-4. The company will make two presentations on preclinical data at the meeting as follows (sessions are virtual so h
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- American Academy of Ophthalmology to Launch its First Open Access Journal in Early 2021https://modernod.com/news/american-academy-of-ophthalmology-to-launch-its-first-open-access-journal-in-early-2021/2477962/The American Academy of Ophthalmology announced plans to expand the Ophthalmology family of journals to include Ophthalmology Science, an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology
- Sanofi Sees Potential Approval of COVID-19 Vaccine in First Half of 2021https://modernod.com/news/sanofi-sees-potential-approval-of-covid-19-vaccine-in-first-half-of-2021/2477923/Sanofi said Tuesday that it expects potential approval of a COVID-19 vaccine being jointly developed with GlaxoSmithKline in the first half of next year, brought forward from an earlier estimate of the second half of 2021. A phase 1/2 study of the recombinant protein-based vaccine approach, whic
- Roche Antibody Test for COVID-19 Goes Live at More Than 20 Initial Lab Sites in the UShttps://modernod.com/news/roche-antibody-test-for-covid-19-goes-live-at-more-than-20-initial-lab-sites-in-the-us/2477797/Roche announced its Elecsys Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout the United States, with plans in the next several weeks to increase to more than 200 commercial and hospital lab sites with the ability t
- GlaxoSmithKline Takes $250 Million Stake in Vir as Companies Pair Up to Develop Coronavirus Treatmentshttps://modernod.com/news/glaxosmithkline-takes-250-million-stake-in-vir-as-companies-pair-up-to-develop-coronavirus-treatments/2477536/GlaxoSmithKline and Vir Biotechnology announced that they have agreed to enter into a collaboration to develop anti-viral antibodies for coronaviruses, including SARS-CoV-2. In addition, to gain access to Vir’s monoclonal antibody technology, GlaxoSmithKline said it will also make an equity
- SparingVision Awarded €2.5 Million at EIC Accelerator Programhttps://modernod.com/news/sparingvision-awarded-e2-5-million-at-eic-accelerator-program/2476715/SparingVision announced that it has been awarded non-dilutive funding of €2.5 million to fund research into retinitis pigmentosa therapies. SparingVision submitted a winning proposal for the European EIC Accelerator (SME instrument phase 2) program. The funding will help speed up SparingVi